跳至主要内容
临床试验/2024-515276-12-00
2024-515276-12-00招募中3 期

TRAnexamic Acid for Preventing blood loss following a cesarean delivery in women with placenta pREVIA: a multicenter randomised, double blind placebo controlled trial. TRAAPrevia

Centre Hospitalier Universitaire De Bordeaux26 个研究点 分布在 1 个国家目标入组 1,380 人开始时间: 2024年9月17日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
1,380
试验地点
26
主要终点
Incidence of red blood cell transfusion between delivery of child and discharge from postpartum hospital stay.

研究概览

简要总结

To compare the effect of a low dose of TXA (1g) administered within 3 minutes after delivery of the child in addition to prophylactic uterotonic in women with placenta previa and cesarean delivery, versus placebo, on the incidence of red blood cell (RBC) transfusion between delivery of child and discharge from postpartum hospital stay

研究设计

分配方式
Randomized
主要目的
Following period
盲法
Double (Monitor, Carer, Investigator, Subject)

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
性别
Female
接受健康志愿者

入选标准

  • Age≥ 18 years
  • Placenta previa defined by a placental edge below 20mm from internal cervical os diagnosed at the most recent transvaginal ultrasound examination before delivery, as per French guidelines
  • Cesarean delivery before or during labor
  • Gestational age at delivery ≥ 32 weeks + 0
  • Affiliated or beneficiary to a health security system
  • Signed informed consent

排除标准

  • History of venous (deep vein thrombosis and/or pulmonary embolism) or arterial (angina pectoris, myocardial infarction, stroke) thrombotic event
  • Placenta praevia diagnosed during delivery
  • Abruptio placentae
  • Significant bleeding (estimated blood loss > 500ml) within 12 hours before cesarean delivery
  • Eclampsia / HELLP syndrome
  • In utero fetal death
  • Administration of low-molecular-weight heparin or antiplatelet agents during the 7 days before delivery
  • Tranexamic acid contraindication
  • Sodium chloride contraindication
  • Women under legal protection
  • Poor understanding of the French language
  • History of epilepsy or seizure
  • Chronic or acute cardiovascular disease (including foramen oval, mitral stenosis, aortic stenosis, heart transplant, pulmonary hypertension)
  • Chronic or acute renal disease (including chronic or acute kidney failure with glomerular filtration rate <90 mL/min, renal transplantation)
  • Chronic active, or acute, liver disorder with hemorrhagic or thrombotic risk (including cirrhosis, portal hypertension, Budd-Chiari syndrome)
  • Active autoimmune disease with thromboembolic risk (including lupus, antiphospholipid syndrome, Crohn’s disease)
  • Sickle cell disease (homozygous)
  • Severe hemostasis disorder  Prothrombotic (Factor V Leiden mutation – homo or heterozygous; Activated protein C (APC) resistance Protein C deficiency, Protein S deficiency aside from pregnancy, Homocysteinemia,; Factor 2 mutation – homo or heterozygous; Deficiency in antithrombin 3),  Prohemorragic such as von Willebrand disease requiring desmopressin treatment during delivery, Thrombocytopenia (< 30 000 /mm3), Glanzmann disease, hypofibrinogenemia (< 1 g/L) aside from pregnancy)
  • High prenatal suspicion of placenta accreta spectrum disorder according to the obstetrician in charge

结局指标

主要结局

Incidence of red blood cell transfusion between delivery of child and discharge from postpartum hospital stay.

Incidence of red blood cell transfusion between delivery of child and discharge from postpartum hospital stay.

次要结局

  • Mean gravimetrically estimated blood loss, by measuring the suction volume and swab weight according to Gai et al (estimated blood loss = (weight of materials used + materials not used - weight of all materials before surgery)/1.05 + volume included in the suction container)
  • Calculated blood loss > 1000 mL. Calculated blood loss = estimated blood volume × (preoperative Ht -postoperative Ht)/preoperative Ht (where estimated blood volume = weight (kg) × 85) [32, 135]. Preoperative Ht will be the most recent Ht within one week before delivery. Postoperative Ht will be measured at day 2 postpartum,
  • Calculated blood loss > 1500 ml
  • Mean calculated blood loss
  • Mean shock index, defined by the ratio of heart rate to systolic blood pressure, measured at 15, 30, 45, 60 and 120 minutes after birth, or if PPH occurs
  • Supplementary uterotonic treatment
  • Iron sucrose perfusion until discharge
  • Number of red blood cell units transfused between delivery of child and discharge from postpartum hospital stay.
  • Proportion of women transfused between delivery of child and 24 hours postpartum
  • Arterial embolisation or emergency surgery for PPH
  • Maternal postpartum transfer to a higher level of care
  • Proportion of breastfeeding at hospital discharge
  • Maternal death for any cause
  • Mean change in peripartum hemoglobin (difference between the most recent Hb within 7 days before delivery and at day 2 postpartum)
  • Mean change in peripartum hematocrit (difference between the most recent Ht within 7 days before delivery and at day 2 postpartum).
  • Occurrence of potential mild adverse reactions of TXA for women : nausea, vomiting, phosphenes, dizziness (these events will be identified in the theatre room as well as during the postpartum stay in hospital);
  • Occurrence of thromboembolic events and other severe unexpected adverse reactions (i.e. incidence of deep vein thrombosis confirmed by radiological exams, pulmonary embolism confirmed by radiological exams, myocardial infarction, seizure, renal failure necessitating dialysis ) - (these events will be assessed up to 12 weeks after the delivery, telephone interview at 12 weeks postpartum)
  • Occurrence of neonatal outcomes: transfer to neonatal ICU.
  • Self-administered questionnaire at day 2 postpartum assessing women’s satisfaction regarding their delivery and their psychological status
  • Self-administered questionnaire sent by mail at 8 weeks of postpartum, assessing their psychological status

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Coordinating investigator

Scientific

Centre Hospitalier Universitaire De Bordeaux

研究点 (26)

Loading locations...

相似试验